Treated like Royalty

Elan Corp. plc (NYSE:ELN) investors didn't seem to mind that Royalty Pharma's $11 per share bid for the company specifically precludes Elan's share buyback plans. Instead, shareholders in the biotech may expect Royalty Pharma to sweeten its bid or for a new suitor to enter the mix, as Elan closed last week at